Dataset Information

Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy

ABSTRACT: Mesenchymal stem cell (MSC) therapy has been shown to be a promising option for liver fibrosis treatment. However, critical factors affecting the efficacy of MSC therapy for liver fibrosis remain unknown. Follistatin-like 1 (FSTL1), a TGF--induced matricellular protein, is documented as an intrinsic regulator of proliferation and differentiation in MSCs. In the present study, we characterized the potential role of FSTL1 in MSC-based anti-fibrotic therapy and further elucidated the mechanisms underlying its action. Human umbilical cord-derived MSCs were characterized by flow cytometry. FSTL1low MSCs was achieved by FSTL1 siRNA. Migration capacity was evaluated by wound-healing and transwell assay. A murine liver fibrotic model was created by carbon tetrachloride (CCl4) injection, while control MSCs or FSTL1low MSC were transplanted via intravenous injection 12 weeks post CCl4 injection. Histopathology, liver function, fibrosis degree, and inflammation were analysed thereafter. Inflammatory cell infiltration was evaluated by flow cytometry after hepatic nonparenchymal cell isolation. An MSC-macrophage co-culture system was constructed to further confirm the role of FSTL1 in the immunosuppressive capacity of MSCs. RNA sequencing was used to screen target genes of FSTL1. FSTL1low MSCs had comparable gene expression for surface markers to wildtype but limited differentiation and migration capacity. FSTL1low MSCs failed to alleviate CCl4-induced hepatic fibrosis in a mouse model. Our data indicated that FSTL1 is essential for the immunosuppressive action of MSCs on inflammatory macrophages during liver fibrotic therapy. FSTL1 silencing attenuated this capacity by inhibiting the downstream JAK/STAT1/IDO pathway. Our data suggest that FSTL1 facilitates the immunosuppression of MSCs on macrophages and that guarantee the anti-fibrotic effect of MSCs in liver fibrosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE202320 | GEO | 2024/04/30

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Mesenchymal stem cell (MSC) therapy improves liver function in patients with liver cirrhosis. However, the therapeutic mechanism underlying MSC therapy remains unclear. Therefore, this study aimed to elucidate the therapeutic mechanism underlying MSC therapy by analyzing changes in the modification and expression of proteins 1-month post-treatment with MSCs. This prospective study included 11 patients with cirrhosis who received MSC injection in the First Hospital of Lanzhou University. The laboratory indexes before and after treatment were collected to evaluate the clinical treatment effect of MSCs, and peptide segments were extracted from liver tissue before and after treatment to revealed the protein expression and lactylation modification. Meanwhile, weighted gene co-expression network analysis was used to analyze co-expression protein modules and their relationship with clinical features. The patients with liver cirrhosis showed an improvement trend after receiving MSC treatment, specifically, the liver protein synthesis function was significantly improved and coagulation function was also significantly improved. Proteomics combined with lactic acid proteomics revealed 160 Lysine lactylation (Kla) sites of 119 proteins. The downregulated lactylated proteins were associated with metabolic processes. The upregulated lactylated proteins were involved in biological processes. The protein-based co-expression module was significantly related to alkaline phosphatase, total bilirubin (TBIL), indirect bilirubin (IBIL), direct bilirubin (DBIL), and ALB, and 10 proteins significantly related to ALB and 10 proteins significantly related to bilirubin were screened. The changes in clinical indexes before and after treatment indicate that the clinical effects of MSC treatment are related to cell metabolism. Overall, this study is the first study to comprehensively and systematically reveal the changes of lactylated proteins and expression after treatment with MSC by the self-control of patients, and lays a foundation for understanding the functions of lactylation modification in MSC therapy.

Dataset Information

Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets